Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.62 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PRKCA | P17252 | 4/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.62 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.54 |
| ▸ | FABP3 | P05413 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167244 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL547251 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL3407184 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL37548 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL3409080 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL16598280 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL42345 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| SCHEMBL15052353 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| Ammonia Solution, Strong SCHEMBL14632885 | 0.99 | ALDH1A1 (0.61) | ALDH1A1LMNALPAR3LPAR1ENPP2 | |
| Ammonia Solution, Strong SCHEMBL14632795 | 0.99 | ALDH1A1 (0.61) | ALDH1A1LMNALPAR3LPAR1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 685 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | NOF CORPORATION (JP) | 2026-04-30 | — | — | US | claimed |
| US-20260108473-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO (US) | 2026-04-23 | — | — | US | claimed |
| US-20260041643-A1 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO (US) | 2026-02-12 | — | — | US | claimed |
| EP-4687853-A1 | LIPID NANOPARTICLE COMPOSITIONS | Københavns Universitet (DK) | 2026-02-11 | — | — | EP | claimed |
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-03 | — | — | US | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4637983-A1 | METHOD FOR PROVIDING A LIPOSOME SOLUTION FOR FORMATION OF MICROVESICLES | DEMCON CURONIX B.V. (NL) | 2025-10-29 | — | — | EP | claimed |
| EP-4626444-A2 | LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS, IONIZABLE LIPIDS, STEROLS, LIPID ANCHORED POLYMERS AND HELPER LIPIDS, THEIR USES | Generation Bio Co. (US) | 2025-10-08 | — | — | EP | claimed |
| EP-4626400-A1 | NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | Generation Bio Co. (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3787601-B1 | LIPOSOMAL NANO FORMULATION OF COMBINATIONAL ANTIBIOTICS AND THE USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2025-10-08 | — | — | EP | claimed |
| WO-2007124465-A2 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-10-25 | — | — | US | claimed |
| EP-0971699-A4 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SKYEPHARMA INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-6241999-B1 | SUBSTITUTING FIRST AMPHIPATHIC LIPID WITH ONE HAVING A SIMILIAR STRUCTURE BUT MORE C ATOMS | SKYEPHARMA, INC. | 2001-06-05 | — | — | US | claimed |
| US-6193998-B1 | INCREASING EFFICIENCY USING MULTIVESICULAR LIPOSOMES CONTAINING PHOSPHOLIPIDS | SKYEPHARMA INC. | 2001-02-27 | — | — | US | claimed |
| US-6171613-B1 | REPLACING AMPHIPATHIC LIPIDS | SKYEPHARMA INC. | 2001-01-09 | — | — | US | claimed |
| US-6132766-A | FOR DRUG DELIVERY SYSTEM; CONTROLLS RELEASE RATE OF ENCAPSULATED BIOLOGICALLY ACTIVE SUBSTANCE INTO BIOLOGICAL FLUIDS AND IN VIVO | SKYEPHARMA INC. (US) | 2000-10-17 | — | — | US | claimed |
| EP-0971699-A1 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SkyePharma Inc. (US) | 2000-01-19 | — | — | EP | claimed |
| US-5997899-A | INCREASING THE NUMBER OF CARBONS IN THE CARBON CHAIN OF AT LEAST ONE LIPID IN THE LIPID COMPONENT OF THE LIPOSOME, WHEREIN THE CHEMICAL STRUCTURES OF THE TWO LIPIDS ARE OTHERWISE SUBSTANTIALLY SIMILAR. | SKYEPHARMA INC. (US) | 1999-12-07 | — | — | US | claimed |
| WO-1998033483-A1 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SKYEPHARMA, INC. (US) | 1998-08-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | SREBF1, SREBF2, FABP1 | ALDH1A1 1605/4885LMNA 101/4885LPAR3 726/4885 |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | CALCR, CALCB, CALCRL | ALDH1A1 3003/4885LMNA 3745/4885LPAR3 77/4885 |
| US-12539338-B2 | Nano-enabled immunotherapy in cancer | IDO1, IDO2, BID | ALDH1A1 1966/4885LMNA 1744/4885LPAR3 139/4885 |
| US-20260041643-A1 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | CD4, CD47, PBK | ALDH1A1 4457/4885LMNA 58/4885LPAR3 129/4885 |
| US-20260108473-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | CD47, PLTP, CETP | ALDH1A1 3178/4885LMNA 199/4885LPAR3 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.